Andromeda Biotech: A drug for type 1 diabetes

November 22, 2011

The treated patients in the double-blinded study of DiaPep 277 showed significantly better pancreas function that the control group.

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their .

DiaPep277 was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. This unique peptide, containing 24 , is derived from the sequence of the human 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of the that secrete insulin and preserving their natural function. Treatment of Type 1 with DiaPep277 may have several medical benefits: slowing the deterioration of the , improved metabolic control, a reduction in daily insulin requirements and fewer complications of diabetes.

During the trial, the ability of the patients' pancreas to secrete insulin was tested. From an initial analysis of the results, it appears that the patients treated with the drug for a year or more had significantly higher pancreas function than those in the control group.

From the point of view of safety, no significant differences were found in the incidence of side effects between the treated and control groups.

Additional data on the drug's efficacy and safety were collected and evaluated, and these will be presented in a final report on the trial, which will be completed in several months.

Andromeda Biotech is now planning to conduct another trial, to try to reproduce these results. Recruitment of patients into this trial is expected to be finalized in the second quarter of 2012. The research and development team of Andromeda Biotech emphasize that the drug is still under development, and there is no absolute guarantee that the drug will eventually be marketed.

Explore further: Landmark trial to evaluate cardioprotective properties of insulin

Related Stories

Promising advances in islet cell transplants for diabetes

June 9, 2008

University of Illinois at Chicago researchers have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells.

Promising results of Phase I diabetes trial announced

June 26, 2011

Promising results of the Phase I clinical trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego. ...

Promising kidney drug fails in large clinical trial

October 27, 2011

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology ...

Recommended for you

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

Team discovers how Zika virus causes fetal brain damage

August 24, 2016

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.